60.41USDMkt Cap: 1.76B USDP/E: —Last update: 2026-05-21
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selectiv…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.76B USD
Enterprise Value1.75B USD
Revenue (TTM)232.39M USD
Gross Profit103.61M USD
Net Income (TTM)-13.23M USD
Revenue/Share8.220 USD
Last Price60.41 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0327241065
Valuation
P/E (Trailing)—
P/E (Forward)10.20
PEG—
EV/EBITDA42.30
EV/Revenue7.53
P/S7.56
P/B137.61
EPS (TTM)-1.02
EPS (Forward)5.92
52W Range
59.0071% of range60.99
52W High60.99 USD
52W Low59.00 USD
Profitability
Gross Margin44.58%
Oper. Margin-135.53%
EBITDA Margin17.79%
Profit Margin-5.64%
ROE-35.56%
ROA-3.63%
Growth
Revenue Growth-8.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF19.70M USD
CapEx (TTM)87.00K USD
FCF Margin3.58%
FCF Yield0.47%
Net Debt-9.10M USD
Net Debt/EBITDA-0.22
Balance Sheet
Debt/Equity0.38
Current Ratio7.58
Quick Ratio7.49
Book Value/Sh0.4390 USD
Cash/Share9.844 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split15:10
Split DateApr 20, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)84.36 USD
Target Range66.00 USD – 140.00 USD
# Analysts11
Ownership
Shares Out.29.10M
Float19.55M
Insiders5.74%
Institutions96.95%
Short Interest
Short Ratio6.3d
Short % Float22.11%
Short % Out.15.33%
Shares Short4.46M
Short (prev mo.)4.81M
Technical
SMA 5052.09 (+16.0%)
SMA 20032.13 (+88.0%)
Beta0.48
S&P 52W Chg28.31%
Avg Vol (30d)396.31K
Avg Vol (10d)540.15K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—